Companies › Valneva Austria
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout May 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VLA1553 Chikungunya virus vaccine | – | Phase 3 | Chikungunya Virus Infection | May 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04838444 | VLA1553 | Phase 3 | Chikungunya Virus Infection | Infectious disease | May 2031 |
Cash of 110m EUR on 2025-12-31; operating cash outflow about 53m EUR a year; runway about 25 months at that burn, to Jan 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
No annotated target.
–
Novavax Chengdu CoenBiotech Biofabri Vedanta Biosciences Osivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.